Arrient Healthcare Pvt Ltd
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Glimpure MV 2.3 Tablet is a combination of anti-diabetic drugs used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels.
Tablet
Glimpure MV 2.3 Tablet is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Glimpure MV 2.3 Tablet is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Glimpure MV 2.3 Tablet.
Glimpure MV 2.3 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Glimpure MV 2.3 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Glimpure MV 2.3 Tablet is a combination of three antidiabetic medicines.
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal. Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
Glimpure MV 2.3 Tablet is a combination of Glimepiride, Metformin, and Voglibose, used to treat type 2 diabetes mellitus (DM). It helps improve blood glucose levels in adults when taken with proper diet and exercise. Glimepiride lowers blood glucose by increasing insulin release from the pancreas. Metformin works by reducing glucose production from the liver and enhancing insulin sensitivity. Voglibose is an alpha-glucosidase inhibitor that lowers postprandial (after meals) glucose levels. This combination is not intended for treating type 1 diabetes.
Possible side effects include hypoglycemia (low blood sugar), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection.
Avoid using this medication if you have known allergies to any of its components or excipients. This medication is also contraindicated in individuals with moderate to severe kidney disease, inflammatory bowel disease, colonic ulcerations, and underlying metabolic acidosis (including diabetic ketoacidosis).
No, combining Glimpure MV 2.3 Tablet with alcohol is not advised. It can lead to lowered blood sugar levels (hypoglycemia) and increase the risk of lactic acidosis.
Yes, Glimpure MV 2.3 Tablet may cause hypoglycemia (low blood sugar level). Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feelings of anxiety or shakiness. This is more likely when you miss meals, drink alcohol, over-exercise, take other antidiabetic medications, or delay food intake.
Store this medicine in its original packaging, tightly closed, according to the label instructions. Dispose of unused medication properly and ensure it is not accessible to pets, children, or others.